Figure 7.Expression of HOXC6, WT1, CD70, and OTP in 54 glioma cases with TERTp mutations. TERTp-mutant glioma samples from 54 glioma patients admitted to our hospital were divided into long- and short-term survival groups based on a survival cut-off of 15 months. (A) IHC scores for HOXC6, WT1, CD70, and OTP expression in glioma samples from patients in the long- and short-term survival groups. (B) Representative IHC images showing the expression of HOXC6, WT1, CD70, and OTP in glioma samples from patients in the long- and short-term survival groups. (C–F) Diagnostic value of HOXC6, WT1, CD70, and OTP for distinguishing long- and short-term survivors among glioma patients with TERTp mutations.
